Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Status
- RECRUITING
- Phase
- PHASE3
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
- Status
- UNKNOWN
- Phase
- PHASE3
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1